Changeflow GovPing Pharma & Drug Safety Methods for Generating Hematopoietic Progenitor...
Routine Notice Added Draft

Methods for Generating Hematopoietic Progenitor Cells

Favicon for changeflow.com ChangeBridge: Patent Apps - Biotech (C12N)
Published
Detected
Email

Summary

The USPTO published patent application US20260092257A1 covering methods for generating human CD34+, CD43+, and CD90+ hematopoietic progenitor cells from hematopoietic stem cells using chemically-defined culture media. The application was filed October 2, 2025, under Application No. 19347888. Inventors include Angelica Gomes Ueltschy and Michael Elias.

What changed

The USPTO published a patent application for methods of generating hematopoietic progenitor cells (CD34+, CD43+, CD90+) from hematopoietic stem cells using chemically-defined culture media. The application covers isolated cell populations and is classified across multiple CPC codes related to cell culture, stem cells, and therapeutic compositions. The filing date was October 2, 2025.

This patent application publication serves as prior art notice to the public and competitors. Researchers and companies developing cell therapies, gene therapies, or regenerative medicine products should review the claims to assess potential freedom-to-operate implications. No compliance deadlines or regulatory requirements are associated with this publication.

What to do next

  1. Review patent claims for freedom-to-operate implications if developing similar cell therapy products
  2. Assess potential licensing opportunities if commercializing related technologies
  3. Update patent landscape monitoring to include this application as prior art

Archived snapshot

Apr 2, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

METHODS AND COMPOSITIONS FOR GENERATING HEMATOPOIETIC PROGENITOR CELLS

Application US20260092257A1 Kind: A1 Apr 02, 2026

Inventors

Angelica GOMES UELTSCHY, Michael Elias

Abstract

The invention provides methods for generating human CD34+, CD43+, and CD90+ hematopoietic progenitor cells from hematopoietic stem cells. The methods include the use of chemically-defined culture media. Isolated cell populations are also provided.

CPC Classifications

C12N 5/0647 C12N 5/0018 C12N 2500/36 C12N 2501/105 C12N 2501/115 C12N 2501/125 C12N 2501/145 C12N 2501/15 C12N 2501/165 C12N 2501/2303 C12N 2501/26 C12N 2506/1353 C12N 2506/1369 C12N 2506/45 C12N 2510/00

Filing Date

2025-10-02

Application No.

19347888

View original document →

Named provisions

Methods for Generating Hematopoietic Progenitor Cells Isolated Cell Populations Chemically-Defined Culture Media

Get daily alerts for ChangeBridge: Patent Apps - Biotech (C12N)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.

Last updated

Classification

Agency
USPTO
Published
April 2nd, 2026
Instrument
Notice
Legal weight
Non-binding
Stage
Draft
Change scope
Minor
Document ID
US20260092257A1

Who this affects

Applies to
Healthcare providers Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing 3254.1 Biotechnology 6211 Healthcare Providers
Activity scope
Biotechnology Research Cell Therapy Development Regenerative Medicine
Geographic scope
United States US

Taxonomy

Primary area
Healthcare
Operational domain
Research and Development
Compliance frameworks
GxP FDA 21 CFR Part 11
Topics
Biotechnology Pharmaceuticals

Get alerts for this source

We'll email you when ChangeBridge: Patent Apps - Biotech (C12N) publishes new changes.

Optional. Personalizes your daily digest.

Free. Unsubscribe anytime.